[Fractalkine level in chronic heart failure of varying severity].

Purpose of research. To examine the level changes of fractalkine in patients with chronic heart failure (CHF) depending on the ejection fraction of the left ventricle and the stage of the disease. MATERIALS AND METHODS: In total 340 people were examined. Of these, 280 patients with CHF divided into groups depending on the ejection fraction of the left ventricle (with a preserved and reduced ejection fraction) and the stage of the disease (stage I to III). Fractalkine level was determined by method of enzyme immunoassay in blood plasma. RESULTS: We revealed an increase in the level of fractalkine in patients with CHF with preserved and reduced ejection fraction compared with the control group. An increase in the level of fractalkine was more pronounced in patients with reduced ejection fraction. In the group of patients with preserved ejection fraction of stage IIB+III, a statistically significant decrease in the level of fractalkin was observed in comparison with patients with stage I to stage III. The method of correlation analysis established that there is a correlation between the level of fractalkine and clinical manifestations of CHF. CONCLUSION: It was revealed an increase in the level of fractalkine in blood plasma in patients with CHF with the control group, which was more pronounced in patients with reduced ejection fraction and the presence of correlation level fractalkine with indicators of clinical manifestations of CHF.

[Association of polymorphism 4a/4b and 4b/4b in endothelial nitric oxide synthase gene and markers of endothelial dysfunction in patients with chronic heart failure].

AIM: To examine the association of polymorphism 4a/4b and 4b/4b in endothelial nitric oxide synthase gene (eNOS) with levels of natriuretic peptide type-C, endothelin-1 and vasoregulative endothelial function in patients with chronic heart failure (CHF) depending on the ejection fraction of the left ventricle. MATERIALS AND METHODS: The study has included 280 patients with CHF of ischemic etiology and 60 somatically healthy individuals. A comprehensive assessment of the markers of the vascular endothelium function was carried out for all patients (endothelial function coefficient, natriuretic peptide type-C, endothelin-1) in association of polymorphism 4a/4b and 4b/4b gene of eNOS. RESULTS: Correlations between the ejection fraction of the left ventricle and the levels of the natriuretic peptide-type C and endothelin-1 have been established. Endothelial dysfunction was revealed in all patients with CHF, but patients with 4a/4b gene of eNOS had more pronounced disorders. The association between the levels of biochemical markers of the endothelial dysfunction with polymorphism 4a/4b gene eNOS was also rervealed. The levels of the natriuretic peptide type C and endothelin-1 were higher in subgroups with genotype 4a/4b of gene eNOS both in patients with CHF with a preserved and with a reduced ejection fraction of the left ventricle. CONCLUSION: In patients with CHF with preserved and reduced ejection fraction of the left ventricle the association of polymorphism 4a/4b gene eNOS with levels of biochemical markers of endothelial dysfunction and vasoregulative endothelial function was revealed.